Fatty liver can trick elastography into overstating fibrosis in hepatitis B — here's the fix.
Aili Wang, Qingqing Wang, and Huaie Liu
In 218 Chinese patients with chronic hepatitis B and low ALT levels, researchers found that moderate-to-severe fatty liver falsely inflated elastography-based fibrosis readings in over a third of patients who did not actually have significant scarring. Using a fat-content threshold from the elastography device's built-in steatosis measurement, they developed adjusted cutoffs that improved diagnostic accuracy and matched biopsy results closely. Applying this steatosis-adjusted approach could help clinicians avoid overestimating fibrosis, and thus avoid unnecessary antiviral escalation, in hepatitis B patients with fatty liver.
- The question: Does fatty liver fool the fibrosis scan in chronic hepatitis B?
- The study: Researchers studied 218 Chinese patients with chronic hepatitis B and low ALT levels.
- The finding: Moderate-to-severe fatty liver falsely inflated fibrosis readings in over a third of patients who did not actually have significant scarring.
- The nuance: Using the elastography device's own built-in fat measurement, researchers developed adjusted cutoffs that matched biopsy results closely.
Takeaway: a steatosis-adjusted approach could help clinicians avoid overestimating fibrosis — and avoid unnecessary antiviral escalation.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.